ANIP Quote, Financials, Valuation and Earnings

Conmed has a net margin of 7.96% compared to ANI Pharmaceuticals's net margin of 1.88%. ANI Pharmaceuticals's return on equity of -4.66% beat Conmed's return on equity of 12.88%.

ANI Pharmaceuticals has a consensus price target of $81.17, signalling upside risk potential of 23.96%. On the other hand Conmed has an analysts' consensus of $66.60 which suggests that it could grow by 27.66%. Given that Conmed has higher upside potential than ANI Pharmaceuticals, analysts believe Conmed is more attractive than ANI Pharmaceuticals.

ANI Pharmaceuticals has a beta of 0.548, which suggesting that the stock is 45.202% less volatile than S&P 500. In comparison Conmed has a beta of 1.236, suggesting its more volatile than the S&P 500 by 23.611%.

ANI Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Conmed offers a yield of 1.53% to investors and pays a quarterly dividend of $0.20 per share. ANI Pharmaceuticals pays -8.77% of its earnings as a dividend. Conmed pays out 18.62% of its earnings as a dividend. Conmed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ANI Pharmaceuticals quarterly revenues are $197.1M, which are smaller than Conmed quarterly revenues of $321.3M. ANI Pharmaceuticals's net income of $15.7M is higher than Conmed's net income of $6M. Notably, ANI Pharmaceuticals's price-to-earnings ratio is 55.43x while Conmed's PE ratio is 13.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals is 1.90x versus 1.23x for Conmed. Usually stocks with elevated PS ratios are considered overvalued.

Novavax has a net margin of 7.96% compared to ANI Pharmaceuticals's net margin of 82.81%. ANI Pharmaceuticals's return on equity of -4.66% beat Novavax's return on equity of --.

ANI Pharmaceuticals has a consensus price target of $81.17, signalling upside risk potential of 23.96%. On the other hand Novavax has an analysts' consensus of $13.43 which suggests that it could grow by 110.64%. Given that Novavax has higher upside potential than ANI Pharmaceuticals, analysts believe Novavax is more attractive than ANI Pharmaceuticals.

ANI Pharmaceuticals has a beta of 0.548, which suggesting that the stock is 45.202% less volatile than S&P 500. In comparison Novavax has a beta of 2.803, suggesting its more volatile than the S&P 500 by 180.302%.

ANI Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ANI Pharmaceuticals pays -8.77% of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend.

ANI Pharmaceuticals quarterly revenues are $197.1M, which are smaller than Novavax quarterly revenues of $626.3M. ANI Pharmaceuticals's net income of $15.7M is lower than Novavax's net income of $518.6M. Notably, ANI Pharmaceuticals's price-to-earnings ratio is 55.43x while Novavax's PE ratio is 2.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals is 1.90x versus 0.87x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.

Steris PLC has a net margin of 7.96% compared to ANI Pharmaceuticals's net margin of 9.84%. ANI Pharmaceuticals's return on equity of -4.66% beat Steris PLC's return on equity of 9.5%.

ANI Pharmaceuticals has a consensus price target of $81.17, signalling upside risk potential of 23.96%. On the other hand Steris PLC has an analysts' consensus of $263.10 which suggests that it could grow by 10.18%. Given that ANI Pharmaceuticals has higher upside potential than Steris PLC, analysts believe ANI Pharmaceuticals is more attractive than Steris PLC.

ANI Pharmaceuticals has a beta of 0.548, which suggesting that the stock is 45.202% less volatile than S&P 500. In comparison Steris PLC has a beta of 0.937, suggesting its less volatile than the S&P 500 by 6.329%.

ANI Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Steris PLC offers a yield of 0.96% to investors and pays a quarterly dividend of $0.57 per share. ANI Pharmaceuticals pays -8.77% of its earnings as a dividend. Steris PLC pays out 35.77% of its earnings as a dividend. Steris PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ANI Pharmaceuticals quarterly revenues are $197.1M, which are smaller than Steris PLC quarterly revenues of $1.5B. ANI Pharmaceuticals's net income of $15.7M is lower than Steris PLC's net income of $145.7M. Notably, ANI Pharmaceuticals's price-to-earnings ratio is 55.43x while Steris PLC's PE ratio is 38.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals is 1.90x versus 4.33x for Steris PLC. Usually stocks with elevated PS ratios are considered overvalued.

Viatris has a net margin of 7.96% compared to ANI Pharmaceuticals's net margin of -93.48%. ANI Pharmaceuticals's return on equity of -4.66% beat Viatris's return on equity of -20.24%.

ANI Pharmaceuticals has a consensus price target of $81.17, signalling upside risk potential of 23.96%. On the other hand Viatris has an analysts' consensus of $11.3875 which suggests that it could grow by 26.39%. Given that Viatris has higher upside potential than ANI Pharmaceuticals, analysts believe Viatris is more attractive than ANI Pharmaceuticals.

ANI Pharmaceuticals has a beta of 0.548, which suggesting that the stock is 45.202% less volatile than S&P 500. In comparison Viatris has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.31%.

ANI Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viatris offers a yield of 5.33% to investors and pays a quarterly dividend of $0.12 per share. ANI Pharmaceuticals pays -8.77% of its earnings as a dividend. Viatris pays out -90.63% of its earnings as a dividend.

ANI Pharmaceuticals quarterly revenues are $197.1M, which are smaller than Viatris quarterly revenues of $3.3B. ANI Pharmaceuticals's net income of $15.7M is higher than Viatris's net income of -$3B. Notably, ANI Pharmaceuticals's price-to-earnings ratio is 55.43x while Viatris's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals is 1.90x versus 0.75x for Viatris. Usually stocks with elevated PS ratios are considered overvalued.